Everything below concerns triple agonist. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Last reviewed on 2025-12-04. Where a claim depends on a specific study, the study is described rather than over-claimed.
Published information places retatrutide in clinical development rather than on the market as an approved therapy. Early-stage and mid-stage trials have examined tolerability and changes in body weight, and larger studies continue to report results over time. Open questions include the durability of effects after treatment stops, the composition of weight lost, and cardiovascular outcomes over long periods. Statements about definitive benefit should therefore be treated as provisional. Regulatory status varies by jurisdiction and changes as applications are reviewed.
Retatrutide is an investigational synthetic peptide designed to activate three distinct receptor systems within a single molecule. Its pharmacological profile combines activity at the glucose-dependent insulinotropic polypeptide receptor, the glucagon-like peptide-1 receptor, and the glucagon receptor. This arrangement places it within a broader class of agents often described as multi-agonists, which contrast with compounds that engage one or two targets. Research interest centers on whether simultaneous signaling produces effects that single-receptor agonists cannot achieve alone. A single molecular entity also simplifies manufacturing and delivery logistics compared with combining separate agents.
Identity and purity are established with reversed-phase high-performance liquid chromatography and mass spectrometry. Chromatographic profiles reveal related impurities, truncated sequences, and oxidation products, while mass measurement confirms the expected molecular mass. Purity values for research material are typically reported as a percentage by peak area. Reference standards help calibrate retention behavior across instruments. Independent laboratories emphasize method suitability because results depend heavily on column chemistry, gradient, and detection wavelength. Batch-to-batch comparison relies on the same validated method.
Investigational peptide material is commonly distributed as a lyophilized powder in sealed vials. The solid form appears as a white to off-white cake or powder and is hygroscopic once opened. Peptides of this size are sensitive to moisture, repeated freeze-thaw cycles, and prolonged exposure to ambient light. Handling practices therefore emphasize desiccation, minimal vial opening, and cold storage. Working aliquots are often prepared to avoid repeatedly warming the bulk container.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic peptide | Studied for metabolic indications |
| Receptor activity | GIP, GLP-1, and glucagon | Single molecule, three targets |
| Development status | Investigational | Not an approved therapy |
| Common synonym | LY3437943 | Development designation |
| Administration route | Subcutaneous injection | As used in clinical studies |
Pharmacologically, retatrutide acts as a triple agonist at the glucagon-like peptide-1 receptor, the glucose-dependent insulinotropic polypeptide receptor, and the glucagon receptor. Activation of the first two receptors is associated with improved insulin secretion and reduced appetite. The glucagon receptor component is thought to increase energy expenditure, a mechanism that distinguishes this molecule from dual-agonist compounds. Researchers continue to investigate how the three activities interact and whether the combined profile offers advantages that justify additional clinical testing.
Several questions about the compound remain unresolved. The durability of weight reduction after treatment stops, the frequency of gastrointestinal side effects, and the long-term cardiovascular profile are topics of ongoing study. Regulatory submissions and phase 3 trial outcomes have not been fully reported in the public literature. Because most available data come from controlled trials rather than general-population use, conclusions about effectiveness outside study settings are provisional. The distinction between established findings and open questions matters when interpreting early coverage of the drug.
Retatrutide is an investigational peptide developed by a pharmaceutical company as a multi-receptor agonist for treating obesity and type 2 diabetes. The compound emerged from research into gut-hormone analogues that act on several receptors simultaneously rather than on a single target. Early preclinical work examined how combined activity at three distinct receptors might produce greater metabolic effects than single-receptor compounds. Published phase 2 results have described substantial reductions in body weight among participants, although the compound remains unapproved in most jurisdictions as of the mid-2020s.
Randomized studies of retatrutide measure change in body weight as a percentage of baseline, along with absolute weight loss. Glycemic endpoints include hemoglobin A1c and fasting plasma glucose. Investigators also track blood pressure, lipid fractions, and liver fat content to characterize effects beyond weight alone. Trial designs typically use double-blind, placebo-controlled groups with periodic dose escalation, and they record adverse events throughout both treatment and follow-up periods.
Quantification of the peptide in biological samples generally relies on liquid chromatography coupled with tandem mass spectrometry. This approach separates the analyte from matrix components and detects it by mass-to-charge transitions specific to the molecule. Immunoassays offer higher throughput but can cross-react with related peptides and metabolites, so mass spectrometric methods are preferred when structural confirmation is required. Method validation typically addresses accuracy, precision, selectivity, and stability under handling conditions.
The intended pharmacology combines three signals in one molecule. GLP-1 receptor activation reduces appetite and slows gastric emptying, effects already exploited by approved incretin-based therapies. GIP receptor engagement is associated with improved insulin sensitivity and with direct effects on adipose tissue, although how much it contributes to overall outcomes is still debated. Glucagon receptor agonism raises energy expenditure and supports hepatic lipid handling, a mechanism that also tends to increase glucose output. The triple profile is hypothesized to produce a larger metabolic effect than single or dual agonism, but the relative weight of each receptor in humans is not settled.
Human evidence remains limited to controlled studies. A phase 2 trial in adults with obesity reported large, dose-dependent reductions in body weight over 48 weeks, with gastrointestinal events as the most frequently recorded adverse effect. Phase 3 programs designated TRIUMPH, for obesity, and TRANSCEND, for type 2 diabetes, are intended to confirm efficacy and to characterize safety in larger populations. Related studies are examining conditions such as knee osteoarthritis in people with obesity and metabolic liver disease. Open questions include long-term tolerability, effects on lean mass, and what happens after treatment is stopped.
Retatrutide is an investigational synthetic peptide that acts on three receptor targets at once: glucose-dependent insulinotropic polypeptide, glucagon-like peptide-1, and glucagon. It is developed by Eli Lilly and appears in the literature and in trial registries under the code LY3437943. The molecule belongs to a class of engineered peptides designed to resist rapid breakdown and permit infrequent subcutaneous administration. No regulatory agency has approved it for clinical use, and all available human data come from controlled trials rather than from routine practice.
Peptide content and purity are commonly measured by reversed-phase high-performance liquid chromatography with ultraviolet detection, using gradient elution over a C18 column. Identity is confirmed by mass spectrometry, because the theoretical monoisotopic mass allows unambiguous assignment of the main component. Impurity profiling resolves deletion sequences, oxidized residues, and truncated fragments. Since the molecule carries a lipophilic side chain, mobile phases often include ion-pairing agents and organic modifiers to keep peaks symmetric.
Lyophilized material is generally held at minus 20 degrees Celsius or colder for long-term storage, protected from moisture and light. Solutions are handled under refrigeration, typically between 2 and 8 degrees Celsius, and used within a short window because degradation and microbial growth both accelerate in liquid. Repeated freeze-thaw cycles are avoided, and vials are equilibrated to room temperature before opening to reduce condensation. These are general laboratory conventions for peptides of this size rather than product-specific directions.
Characterization panels may add amino acid analysis for compositional confirmation, circular dichroism for secondary structure in solution, and light scattering for aggregation tendency. Aggregation is a central concern for peptides bearing hydrophobic side chains, since it can lower measured potency and complicate accurate dosing. Stability studies examine temperature, humidity, pH, and light exposure over defined intervals, reporting the percentage of intact peptide remaining. Results depend strongly on the assay used, so comparing values across studies requires matching method details.
===== Triple combination ===== The combination of metformin with dapagliflozin and saxagliptin is available in the United States as Qternmet XR. The combination of metformin with pioglitazone and glibenclamide is available in India as Accuglim-MP, Adglim MP, and Alnamet-GP; and in the Philippines as Tri-Senza. The combination of metformin with pioglitazone and lipoic acid is available in Turkey as Pional.
Contrary to popular belief, nicotine itself does not cause cancer in humans, although it is unclear whether it functions as a tumor promoter as of 2012. A 2018 report by the US National Academies of Sciences, Engineering, and Medicine concludes, "[w]hile it is biologically plausible that nicotine can act as a tumor promoter, the existing body of evidence indicates this is unlikely to translate into increased risk of human cancer." Although nicotine is classified as a non-carcinogenic substance, it can still theoretically promote tumor growth and metastasis as evidenced from alterations. Nicotine induces several processes, some of them via nicotine's effects on immune function, that contribute to cancer progression in both smoking-related and non-smoking-related cancers, including cell cycle progression, epithelial-to-mesenchymal transition, migration, invasion, angiogenesis, and evasion of apoptosis. These effects are primarily mediated through nicotinic acetylcholine receptors (nAChRs), particularly the α7 subtype, and to a lesser extent, β-adrenergic receptors (β-ARs). Activation of these receptors triggers several signaling cascades crucial in cancer biology, notably the MAPK/ERK pathway, PI3K/AKT pathway, and JAK-STAT signaling. Nicotine potentially promotes lung cancer development by enhancing proliferation, angiogenesis, migration, invasion, and epithelial–mesenchymal transition (EMT) via nAChRs, which are present in lung cancer cells. Additionally, nicotine-induced EMT contributes to drug resistance in cancer cells.
The classical description of myiasis is according to the part of the host that is infected. This is the classification used by ICD-10. For example: dermal sub-dermal cutaneous (B87.0) creeping, where larvae burrow through or under the skin furuncular, where a larva remains in one spot, causing a boil-like lesion nasopharyngeal, in the nose, sinuses or pharynx (B87.3) ophthalmic or ocular, in or about the eye (B87.2) auricular, in or about the ear gastric, rectal, or intestinal/enteric for the appropriate part of the digestive system (B87.8) urogenital (B87.8) Another aspect is the relationship between the host and the parasite which provides insight into the biology of the fly species causing the myiasis and its likely effect. Thus the myiasis is described as either: obligatory, where the parasite cannot complete its life cycle without its parasitic phase, which may be specific, semispecific, or opportunistic facultative, incidental, or accidental, where it is not essential to the life cycle of the parasite; perhaps a normally free-living larva accidentally gained entrance to the host Accidental myiasis commonly is enteric, resulting from swallowing eggs or larvae with one's food. The effect is called pseudomyiasis. One traditional cause of pseudomyiasis was the eating of maggots of cheese flies in cheeses such as Stilton. Depending on the species present in the gut, pseudomyiasis may cause significant medical symptoms, but it is likely that most cases pass unnoticed.
The Revolt, written by Menachem Begin before he became Prime Minister, tells the story of the Lehi (referred to by their translated name's acronym, F.F.I. "Freedom Fighters of Israel" in early English editions) and Begin's own Irgun fighters during the Jewish insurgency in Palestine. The Revolt influenced groups from a wide variety of ideologies. Some of these groups began to use suicide attacks in the 1990s. The book was allegedly found Osama bin Laden's al-Qaeda organization. Begin praised his militants' willingness to die, "These two wonderful young men greeted the sentence with the singing of Hatikvah". The "two wonderful young men" were the two who blew themselves up in 1947, he described their deaths, "even before they put on their red uniforms. They too held their heads high when they faced their judges… But they did not reach the gallows. They too sang on the threshold of death — a song of faith in God: 'Lord of the world who reigned before creation'. But their song ended with a great explosion which shattered the silence of the prison in occupied Jerusalem". In 1977 the author became prime minister, after previously being in opposition. Historical militants featured prominently in his political speeches. He praised the actions of his militants during the insurgency in Palestine in the 1940s, including the leader of the cell who bombed the King David Hotel (killing 91 people and 1 terrorist). His favourites were, again, the two young militants who blew themselves up in Jerusalem prison in 1947.
== Personal life == Sherman met and married Hildegard Schroeder while they were both graduate students at the University of Iowa, and they had three children: Karen, Marc, and Keith. In addition to his professional activities, he has participated in organizations such as the Boy Scouts of America, the Jewish War Veterans organization, and the Lions Club. Sherman died on December 1, 2023, at the age of 98.
Sources: en.wikipedia.org
=== Disease models === Various animal models of disease are used to understand the pathogenesis and etiology of type 1 diabetes. Currently available models of T1D can be divided into spontaneously autoimmune, chemically induced, virus-induced, and genetically induced. The nonobese diabetic (NOD) mouse is the most widely studied model of type 1 diabetes. It is an inbred strain that spontaneously develops type 1 diabetes in 30–100% of female mice depending on housing conditions. Diabetes in NOD mice is caused by several genes, primarily MHC genes involved in antigen presentation. Like diabetic humans, NOD mice develop islet autoantibodies and inflammation in the islet, followed by reduced insulin production and hyperglycemia. Some features of human diabetes are exaggerated in NOD mice, namely the mice have more severe islet inflammation than humans, and have a much more pronounced sex bias, with females developing diabetes far more frequently than males. In NOD mice, the onset of insulitis occurs at 3–4 weeks of age. The islets of Langerhans are infiltrated by CD4+, CD8+ T lymphocytes, NK cells, B lymphocytes, dendritic cells, macrophages, and neutrophils, similar to the disease process in humans. In addition to sex, breeding conditions, gut microbiome composition or diet also influence the onset of T1D. The BioBreeding Diabetes-Prone (BB) rat is another widely used spontaneous experimental model for T1D. The onset of diabetes occurs, in up to 90% of individuals (regardless of sex) at 8–16 weeks of age.
== Function == GnRH is secreted in the hypophysial portal bloodstream at the median eminence. The portal blood carries the GnRH to the pituitary gland, which contains the gonadotrope cells, where GnRH activates its own receptor, gonadotropin-releasing hormone receptor (GnRHR), a seven-transmembrane G-protein-coupled receptor that stimulates the beta isoform of Phosphoinositide phospholipase C, which goes on to mobilize calcium and protein kinase C. This results in the activation of proteins involved in the synthesis and secretion of the gonadotropins LH and FSH. GnRH is degraded by proteolysis within a few minutes. GnRH activity is elevating during fetal life, drops briefly following birth due to the effect of placental hormones, then becomes elevated again for the first one to six months of life in a period known as minipuberty, during which time gonadotropins and sex steroids contribute to the development of sexual organs. GnRH is very low during childhood, and is reactivated at puberty during adolescence. During the reproductive years, pulse activity is critical for successful reproductive function as controlled by feedback loops. However, once a pregnancy is established, GnRH activity is not required. Pulsatile activity can be disrupted by hypothalamic-pituitary disease, either dysfunction (i.e., hypothalamic suppression) or organic lesions (trauma, tumor). Elevated prolactin levels decrease GnRH activity. In contrast, hyperinsulinemia increases pulse activity leading to disorderly LH and FSH activity, as seen in polyendocrine metabolic ovarian syndrome (PMOS).
=== Photoaffinity labeling === Unlike ABPP, which results in protein labeling upon probe binding, photoaffinity labeling probes require activation by photolysis before covalent bonding to a protein occurs. The presence of a photoreactive group makes this possible. These probes are composed of three connected moieties: (1) a drug scaffold; (2) a photoreactive group, such as an phenylazide, phenyldiazirine, or benzophenone; and (3) an identification tag, such as biotin, a fluorescent dye, or a click chemistry handle. The drug scaffold is typically an analog of a drug whose mechanism is being studied, and, importantly, binds to the target reversibly, which better mimics the interaction between most drugs and their targets. There are several varieties of photoreactive groups, but they are fundamentally different from ABPP probes: while ABPP specifically labels nucleophilic amino acids in a target's active site, photoaffinity labeling is non-specific, and thus is applicable to labeling a wider range of targets. The identification tag will vary depending on the type of analysis being done: biotin and click chemistry handles are suitable for enrichment of labeled proteins prior to mass spectrometry based identification, while fluorescent dyes are used when using a gel-based imaging method, such as SDS-PAGE, to validate interaction with a target.
. The superscript "+" indicates the ion charge and the superscript "•" indicates an unpaired electron of the radical ion. The energy of the electron beam is typically 70 electronvolts and the ionization process typically produces extensive fragmentation of the chemical bonds of the molecule. Due to the high vacuum pressure in the ionization chamber, the mean free path of molecules are varying from 10 cm to 1 km and then the fragmentations are unimolecular processes. Once the fragmentation is initiated, the electron is first excited from the site with the lowest ionization energy. Since the order of the electron energy is non-bonding electrons > pi bond electrons > sigma bond electrons, the order of ionization preference is non-bonding electrons > pi bond electrons > sigma bond electrons.
Sources: en.wikipedia.org
== Career == Thomsen worked as a pharmacologist at Leo Pharma from 1989 to 1991 and was thereafter employed by Novo Nordisk in as head of Growth Hormone Research. He became senior vice president for diabetes R&D in 1994 and was appointed senior vice president of Health Care Discovery in 1995. In November 2000, he was appointed executive vice president of Global R&D and chief scientific officer (CSO). As chief scientific officer, he was responsible for the research and development of 20 medicine products within diabetes, obesity and biopharmaceuticals. He led the development of GLP-1 therapies that today are among the leading treatments within type 2 diabetes and obesity. He left the position as executive vice president of R&D on February 28, 2021, and took the role as CEO of the Novo Nordisk Foundation on March 1, 2021. He has been the president of the Danish Academy of Technical Sciences and has been on the board of directors at the Technical University of Denmark (DTU) and University of Copenhagen. From 2017 to 2020, Thomsen was the chairman of the board of directors at University of Copenhagen. Mads Krogsgaard Thomsen received the royal decoration of Knight of the Order of the Dannebrog by the Danish Royal House on 12 December 2022. In 2024, Thomsen received the Golden Plate Award of the American Academy of Achievement, presented by Awards Council member Robert S. Langer.
It controls trunk muscles and part of the sympathetic nervous system. Tonic receptor A sensory receptor that continues to fire throughout the duration of a stimulus. Contrasts with phasic receptors, which adapt quickly. Tonic-clonic seizure A type of generalized seizure involving an initial tonic phase of muscle stiffening followed by a clonic phase of rhythmic jerking. Often accompanied by loss of consciousness. Top-down processing Perception driven by cognition — the brain applies what it knows and expects to what it sees. In contrast to bottom-up processing. Transcranial direct current stimulation (tDCS) A noninvasive brain stimulation technique that applies a low electrical current to the scalp to modulate neuronal excitability. Transcranial magnetic stimulation (TMS) A noninvasive method to stimulate or inhibit brain activity using magnetic fields. Used in both research and treatment for depression and other disorders. Transduction The process of converting a physical stimulus (e.g., light, sound, touch) into an electrical signal in sensory receptors. Trigeminal nerve (Cranial Nerve V) The largest cranial nerve, responsible for sensation in the face and motor control of biting and chewing. Trophic factor A substance, such as nerve growth factor (NGF), that supports the growth, survival, and differentiation of neurons. Tuberomammillary nucleus A small cluster of histaminergic neurons in the hypothalamus involved in arousal, attention, and the sleep–wake cycle. Two-point discrimination The ability to distinguish two closely spaced tactile stimuli as separate.
Richmond-Bridgeport MLA Teresa Wat claims Findlay made “unfounded accusations about me, including remarks that called my allegiance to Canada into question,” stating she "cannot continue to sit in a caucus led by someone who has questioned my loyalty without evidence and, when given the opportunity to correct the record, has failed to do so.” Courtenay-Comox MLA Brennan Day issued a statement criticizing Findlay's leadership, writing "I have lost confidence in the judgement, conduct, and ethical standards of her leadership and those she has chosen to surround herself with." Abbotsford South MLA Bruce Banman, the first MLA to cross the floor and join John Rustad as a Conservative, wrote "person after person has informed me they have decided that our new leader is unelectable," instead he is "joining an ever increasing number of MLAs to sit as an independent MLA in the BC Legislature". Banman also wrote he "would encourage my fellow MLAs regardless of political affiliation to join me." Boundary-Similkameen MLA Donegal Wilson cited Findlay's hiring of "Alberta separatist[s]" as the reason for her resignation, along with Findlay's inability to "bring Conservatives back together.” MLAs Ian Paton of Delta-South, Peter Milobar of Kamloops Centre, Rosalyn Bird of Prince George-Valemount, Áʼa꞉líya Warbus of Chilliwack-Cultus Lake, Scott McInnes of Columbia River-Revelstoke, and Linda Hepner of Surrey-Serpentine River also announced their resignation from the party. In September 2026, Findlay removed three MLAs from the Conservative caucus for questioning her leadership.
Sources: en.wikipedia.org
It is described as a single molecule that acts at three receptors: the glucose-dependent insulinotropic polypeptide receptor, the glucagon-like peptide-1 receptor, and the glucagon receptor. This triple activity distinguishes it from agents that target one or two of these pathways.
It is characterized in the literature as an investigational agent under clinical study. Approval status depends on jurisdiction, and readers should check current regulatory information rather than assume availability.
The combination is intended to pair appetite-related and glucose-related effects with mechanisms that increase energy expenditure. Whether the combined profile offers advantages over simpler agonists is the subject of ongoing research.
Solid powder is held frozen at -20 °C or below in a desiccated container. Reconstituted solutions are refrigerated and used within a limited period.